# The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

> **NCT07272265** · NA · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 300 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Atezolizumab & Bevacizumab
- **PROCEDURE:** FOLFOX-HAIC

## Key facts

- **NCT ID:** NCT07272265
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-28
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-11-10
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07272265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07272265, "The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07272265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*